NPRA Banner

               
Product Search   QUEST3+ System   Enquiries   Sitemap  

Ofev® (nintedanib): Information on severe liver injury and the need for regular monitoring of liver function associated with the use in patients with idiopathic pulmonary fibrosis (IPF)

User Rating: 4 / 5

Star ActiveStar ActiveStar ActiveStar ActiveStar Inactive
 

 

Date: 5 January 2018

 

Description:

Cases of drug-induced liver injury (DILI) in patients treated with Ofev® have been reported worldwide in the post-marketing period, including a case of severe liver injury associated with a fatal outcome.

Healthcare professionals are advised to monitor transaminases and bilirubin levels:

  • just before starting treatment;
  • at regular intervals during the first three months of treatment; and
  • periodically thereafter (e.g. at each patient visit) or as clinically indicated.

Dose reduction or treatment interruption is recommended for managing transaminase elevations according to the current product information.

 

Please refer to the Direct Healthcare Professional Communication (DHPC) letter issued by Boehringer Ingelheim (Malaysia) Sdn. Bhd. in agreement with NPRA for further information.

 

 

National Pharmaceutical Regulatory Agency (NPRA)

Lot 36, Jalan Universiti (Jalan Prof Diraja Ungku Aziz), 46200 Petaling Jaya, Selangor, Malaysia.

  • Phone: +603-7883 5400

 

 

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Site Last Modified

  • Last Modified: Monday 14 October 2024, 12:31:07.

Search

Main Menu English